Journal
CURRENT ATHEROSCLEROSIS REPORTS
Volume 18, Issue 3, Pages -Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11883-016-0565-6
Keywords
Coronary artery calcium; Coronary heart disease; Cardiovascular disease; Risk assessment; Primary prevention; Statins
Categories
Funding
- NIH/NHLBI
- American Heart Association
- Aetna Foundation
- FDA
- Pfizer
- Novartis
- Aralez Pharmaceuticals
- Luitpold Pharmaceuticals
- ISIS Pharmaceuticals
Ask authors/readers for more resources
Estimating cardiovascular disease (CVD) risk is necessary for determining the potential net benefit of primary prevention pharmacotherapy. Risk estimation relying exclusively on traditional CVD risk factors may misclassify risk, resulting in both undertreatment and overtreatment. Coronary artery calcium (CAC) scoring personalizes risk prediction through direct visualization of calcified coronary atherosclerotic plaques and provides improved accuracy for coronary heart disease (CHD) or CVD risk estimation. In this review, we discuss the most recent studies on CAC, which unlike historical studies, focus sharply on clinical application. We describe the MESA CHD risk calculator, a recently developed CAC-based 10-year CHD risk estimator, which can help guide preventive therapy allocation by better identifying both high-and low-risk individuals. In closing, we discuss calcium density, regional distribution of CAC, and extra-coronary calcification, which represent the future of CAC and CVD risk assessment research and may lead to further improvements in risk prediction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available